An international team led by scientists at The Scripps Research Institute (TSRI), the Howard Hughes Medical Institute and Albert Einstein College of Medicine of Yeshiva University has identified a highly promising new anti-tuberculosis compound that attacks the tuberculosis (TB) bacterium in two different ways.
These findings represent an effort to help solve one of the major global health crises of our timethe resurgence of TB and its dangerous drug-resistant strains, says Peter G. Schultz, the Scripps Family Chair Professor of Chemistry at TSRI, who was senior author of the study with William R. Jacobs, Jr., member of the Howard Hughes Medical Institute and professor of microbiology & immunology and of genetics at Albert Einstein College of Medicine.
In cell cultures and in mice, this compound showed powerful activity against ordinary active TB bacteria, non-replicating TB bacteria and even extensively drug-resistant TB strains, says Feng Wang, a member of the Schultz lab at TSRI and first author of the study with Dhinakaran Sambandan of the Jacobs lab and Rajkumar Halder of the Schultz lab.
The paper appears in this week online ahead of print in an Early Edition of the Proceedings of the National Academy of Sciences.
Although isoniazid and rifampin, the two front-line TB drugs, came into use in 1952 and 1967 respectively, new TB infections still occur at the rate of roughly one per second. At any moment about a third of the existing human population is infectedmostly with inactive, latent TB, although active TB still kills over one million people each year. Russia, Africa, China and Southeast Asia have been especially hard hit by the epidemic.
Increased urbanization, public health complacency and immunity-weakening HIV have been major enablers of TBs spread in recent decades. But the bacterium that causes TBMycobacterium tuberculosis (Mtb)also happens to be unusually well adapted for persisting in humans. Among other strategies, it frequently reverts to a dormant, non-replicating state and also creates attack-resistant cell colonies called biofilms, which contain a high proportion of non-replicating TB.
Compared to ordinary, fast-replicating TB, these other forms of TB are much less susceptible to existing drugs. Effective TB therapy thus requires months to years of regular dosing. But many patients quit before completing such long courses of treatment and end up incubating drug-resistant TB strains. Some strains are now extensively drug-resistant (XDR) and virtually untreatableand usually fatal.
Â The big challenge here has been to find a drug that clears TB infection more quickly, which means it has to be effective against both replicating and non-replicating TB, says Wang, now also a scientist at the California Institute for Biomedical Research (CALIBR), a non-profit organization founded by Schultz for the early-stage development of new medicines.
Most existing TB drugs work poorly against non-replicating TB, having been developed principally for their ability to kill actively replicating TB. Wang therefore set up a different kind of screening testone to detect compounds that block TBs persistence-related ability to form biofilms.
Because experiments with live TB require a special (level 3) biosafety facility, Wang used a related but non-disease-causing mycobacterium for his initial, high-throughput test. Screening a diverse library of 70,000 compounds, he quickly found one, dubbed TCA1, that stood out for its ability to inhibit mycobacterial biofilms.
Tests in Jacobss biosafety level 3-certified laboratory confirmed that TCA1 also has powerful activity against TB. Surprisingly, it turned out to kill both non-replicating and replicating TB, Wang says.
In cell culture tests, TCA1 on its own killed more than 99.9 percentÂ of ordinary, actively replicating TB bacteria within three weeks, and in combination with isoniazid or rifampin, could kill 100% within that period. TCA1 also showed strong effectiveness against drug-resistant TB strains, removing all signs of one common strain within a week when combined with isoniazid. Against a highly fatal super-bug strain from South Africa, which resists all conventional TB drugs, the new compound on its own had a kill rate of more than 99.999 percentÂ within three weeks.
As expected, TCA1 also showed potent effects against non-replicating TB. Tests in mice confirmed TCA1s effectiveness and suggested that the combination of TCA1 and isoniazid could be more powerful than existing drug regimens. TCA1 showed no sign of toxicity or adverse side effects in cell culture and mouse experiments, and also showed almost no tendency to induce drug resistance in TB.
Working with the laboratories of Gurdyal S. Besra and Klaus FÃ¼tterer at the University of Birmingham, UK, Katarina Mikusova at Comenius University in Slovakia, and Kai Johnson at Ecole Polytechnique FÃ©dÃ©rale de Lausanne (EPFL) in Switzerland, the team next did structural and biochemical analyses to determine how the new compound kills Mtb so efficiently.
The researchers found it works in an apparently unique way, largely by targeting two Mtb enzymes, one supporting TB replication and the other TB dormancy and persistence. I dont know of any other antibiotic that kills replicating bacteria through one pathway and non replicating bacteria through another, as this one does, Wang said.
Now funded by the Global Alliance for TB Drug Development, Wang and his colleagues are working to devise improved variants of TCA1. We already have analogs of TCA1 that are more potent and look very promising as TB drug candidates, says Wang.
Assuming that preclinical tests are completed successfully, he added, the group hopes to find a pharmaceutical company partner to sponsor clinical trials in TB patients.
Contributors to the study, Identification of a small molecule with activity against drug-resistant and persistent tuberculosis, also included Jianing Wang, Insha Ahmad, Pengyu Yang and Yong Zhang of TSRI; Sarah M. Batt of University of Birmingham; Brian Weinrick, John Kim and Morad Hassani of Howard Hughes Medical Institute and Albert Einstein College of Medicine; Stanislav Huszar of Comenius University (Slovakia); Claudia Trefzer of EPFL; Zhenkun Ma, Takushi Kaneko and Khisi E. Mdluli of the Global Alliance for Tuberculosis Drug Development; Scott Franzblau of the University of Illinois; and Arnab K. Chatterjee of CALIBR.
The study was funded in part by the National Institutes of Health (grants AI26170 and A10-97548), the European Communitys Seventh Framework Programme (260872), the Global Alliance for TB Drug Development and the Albert Einstein College of Medicine Center for AIDS Research (AI051519).
Source: Scripps Research Institute